Sagittarius Life Science Corp.

Sagittarius Life Science Corp.

TTPEX:3205
42.50
TWD
-0.35
(-0.82%)
-0.25EPS
3.52BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
11.3
16.78
46.1
44.69
14.12
12.55
13.39
17.11
18.05
16.26
13.53
14.37
10.63
6.59
Basic EPS, GAAP
0.02
0.39
11.18
8.66
-3.48
-2.8
-3.65
-2.27
-2.66
-2.28
-1.69
-1.49
-1.52
-0.23
Free Cash Flow per Basic Share
-4.12
1.96
8.7
11
-0.8
-1.78
-3.65
-2.25
-1.16
-1.66
-2.19
-1.48
-1.12
-3.68
Dividend per Share
- -
- -
- -
2.76
4
1.61
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
10.03
10.42
25.64
36.98
29.46
24.33
20.57
18.01
15.88
13.57
15.81
12.55
15.43
14.82
Tangible Book Value per Share
8.26
9.1
24.76
36.39
29.16
24.17
20.52
18
15.87
13.57
15.81
12.53
15.43
14.82
Basic Weighted Avg Shares
26
26
27
31
33
33
33
33
33
33
33
33
33
71
Sales/Revenue/Turnover
295
439
1,240
1,384
463
411
439
558
588
529
440
468
346
468
Operating Margin (%)
-9.52
0.4
24.32
25.88
-17.78
-27.86
-23.96
-12.86
-15.32
-15.54
-14.62
-13.16
-16.91
-7.01
Depreciation Expense
15
18
17
14
14
12
26
26
24
21
15
15
10
7
Net Income, GAAP
1
10
301
268
-114
-92
-120
-74
-86
-74
-55
-49
-50
-16
Effective Tax Rate (%)
- -
15.82
7.01
23.96
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
0.19
2.3
24.25
19.37
-24.68
-22.32
-27.24
-13.28
-14.71
-14.02
-12.5
-10.38
-14.32
-3.52
Working Capital
167
188
599
1,062
820
616
490
382
322
258
206
159
801
749
LT Debt
92
95
36
- -
- -
- -
22
22
13
3
6
4
- -
- -
Total Equity
262
272
715
1,212
965
797
675
588
532
455
527
420
1,045
1,003
Return on Invested Capital (%)
- -
0.4
49.2
26.58
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
3.35
53.63
27.18
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
0.22
3.77
60.92
27.84
-10.49
-10.42
-16.24
-11.76
-15.67
-15.48
-11.51
-10.52
-6.83
-1.6

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
23
73
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
68
68
68
Market Capitalization
3,465
4,222
3,519

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
827
856
882
Cash, Cash Equivalents & STI
804
716
635
Accounts Receivable, Net
10
61
49
Inventories
9
33
85
Total Current Liabilities
26
73
133
Payables & Accruals
- -
- -
- -
ST Debt
- -
23
73
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.39%
24.06%
148.9%
Free Cash Flow
9.66%
-5.98%
-24.5%
Net Income, GAAP
-21.39%
-6.61%
2.13%
Sales/Revenue/Turnover
-7.34%
-8.25%
-26.01%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
117
118
114
118
468
2025
101
113
93
40
346
2026
147
188
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.29
-0.5
-0.45
-0.25
-1.49
2025
-0.23
-0.33
-0.1
-0.17
-1.52
2026
0.05
-0.02
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Le Wei Chen
Full Time Employees
112
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No.3, Yuanqu Street Taipei TP Taiwan
IPO Date
May 28, 2004
Business
Sagittarius Life Science Corp (3205.TWO) engages in the research, development, production, and sale of Chinese and western medicines, health food products, organic food, daily necessities, and pet food in Taiwan and Asia. The company specializes in biotechnology research with a focus on plant-derived new drugs, nutrition and health care products, skin care products, and immune adjustment, beauty, anti-aging, and antioxidant supplements; it also provides technical services for biochemical product development, customized formulation design, and contract manufacturing of patented products. Founded in 1998 and headquartered at 10F-6, No. 3, Yuanqu Street, Nangang District, Taipei, Taiwan, Sagittarius Life Science operates primarily in the healthcare and biotechnology sectors, targeting consumer health markets through self-branded sales and professional distribution networks across domestic and regional channels. Recent financial reports indicate ongoing revenue from core operations amid market challenges, with 2025 year-to-date sales at approximately NT$3.23 billion as of October, reflecting year-over-year declines but sustained R&D efforts in natural herbal extracts and clinical-stage botanical pharmaceuticals undergoing Phase II trials in Taiwan and China.